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>50 years (P ¼ .56). Patients with DCB transplant had 63%
infections vs. 31% in the other transplant types (P ¼ .059).
Gram-positive cocci were isolated in 57% and Gram-negative
rods in 26% of all infections. DVT occurred in 26% of all cases.
DVT rates according to the presence or absence of a particular
catheter type were 27% vs. 25% for Hickman, 37% vs. 17% for
PICC (P ¼ .1) and 14% vs. 29% for IP (P ¼ .6). In patients with
only one catheter type, DVT rates were 17% for Hickman vs.
25% for PICC (P¼ .4). DVToccurred in 18% of patients 50 years
of age or younger and in 47% of those >50 years (P ¼ .026).
Conclusion: Among AML patients who underwent HSCT at
our institution, we did not observe any signiﬁcant differences
in catheter-related complications according to catheter type.
DVT rate was signiﬁcantly higher in patients older than 50
years. There was a trend of higher infection rate with double
cord blood transplant compared to other transplant types.309
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This information is intended to give background and inter-
vention options for healthcare professionals in the transplant
outpatient setting dealing with patients that are at risk for
suicide.
In 2007, there were 34,598 deaths by suicide in the United
States. Suicide is the fourth leading cause of death in adults,
ages 18 to 65 years. According to the Annals of Oncology
persons diagnosed with cancer have double the risk of
committing suicide compared to the general population.
It is important to identify those patients who are at greatest
risk of suicide. Symptoms of suicidal ideation include feelings
of hopelessness, anhedonia, insomnia, depression, severe
anxiety, impaired concentration, psychomotor agitation,
panic attack, and severe remorse. The Health Care Provider
needs to establish an atmosphere of trust to encourage the
patient to express their current symptoms. There are tools
available for health care providers in outpatient clinics that
can provide the ability to calculate the patient's risk. Some of
those tools include but are not limited to the Beck Scale, BSI
18, and SAFE T.
This program has experienced loss due to suicide in the past
several years. The program subsequently developed a suicide
protocol to help identify those patients at greatest risk for
suicide. The entire staff was trained on suicidal ideations and
at risk behaviors. When the staff identiﬁes a potential suicide
risk the team is called and further evaluation is completed.
The suicide protocol team consists of a nurse and social
worker. The process is explained to the patient and caregiver.
The nursemanager and the patient's physician are notiﬁed of
the situation. A family member or another staff member stay
with the patient at all times to maintain a safe environment.
We have identiﬁed a crisis team with a nearby psychiatric
facility that will provide further evaluation and recommend
a plan, if the patient is determined to be at risk for suicide. If
the patient appears safe to return home the patient and
family are instructed how tomake the home safe. The patient
will receive a follow up phone call and continued
monitoring.
Since the initiation of this protocol the facility has not had
a suicide attempt or completion.310
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Background: Radiation dermatitis is a frequent complication
following TBI based preparative regimens. There is no
consistent approach to the diagnosis and management of
radiation dermatitis. Many of the topical therapies have side
effects such as skin discoloration and discomfort in the case
of silver sulfadiazine. Newer silver containing agents such as
Silvasorb gel, Melgisorb Ag and Mepilex Ag may facilitate
healing and increase patient comfort.
Objective: To develop a consistent approach to diagnosis and
management of radiation dermatitis and to assess the clinical
outcomes in a pilot study.
Patients: From 2010 to 2012 thirteen patients who under-
went allogeneic BMT following a preparative regimen con-
sisting of 1200 cGy fractionated TBI and Cytoxan (60 mg/kg/
day x 2 days) were evaluated. All patients received daily
topical treatment with a moisturizing barrier cream (Aqua-
phor). Patients were evaluated daily for dermatitis. Radiation
dermatitis was graded according to CTCAE (version 3). Five
patients developed radiation dermatitis between days 0 to 2
post transplant.
Treatment and Results: All of the patients were treated
according to a previously developed algorithm. Two patients
with Grade 2 dermatitis were treated with Silvasorb gel
applied twice daily and reinforced with Xeroform gauze. The
skin lesions did not progress and was restored by day 5.
Three patients who progressed to Grade 3 dermatitis were
initially treated with Silvasorb gel, and the treatment was
changed to Melgisorb (ag) or Mepilex (ag). None of the
patients progressed to Grade 4. The skin lesions in all 3
patients with Grade 3 dermatitis was restored by Day 10 post
transplant and the therapy was discontinued.
Conclusions:
 CTCAE version 3 for assessing dermatitis represents
a useful and consistent tool for deﬁning radiation
dermatitis and allows for early intervention.
 The newer silver containing agents are well tolerated
and in this small series, effective in promoting healing.
 Based on our results an algorithm for early diagnosis
and treatment of grade 2-3 radiation dermatitis was
established.311
Incidence and Outcomes of Fungal Infections in Children
Undergoing Allogeneic Hematopoietic Stem Cell
Transplantation (HCT): Eight Years Single Center
Experience
Gregory Wallace 1, Stella Davies 1, Alexandra Filipovich 1,
Beverly Connelly 2, Michael Cloughessy 2, Jack Bleesing 1,
Sharat Chandra 1, Michael Grimley 1, Sonata Jodele 1,
Michael Jordan 1, Ashish Kumar 1, Rebecca A. Marsh 1,
Kasiani Myers 1, Denise Bellman 1, Parinda A. Mehta 1. 1 Bone
Marrow Transplantation and Immune Deﬁciency, Cincinnati
Children's Hospital Medical Center, Cincinnati, OH; 2 Pediatric
